Enterprise Value

2.285B

Cash

810.3M

Avg Qtr Burn

-100.2M

Short % of Float

0.03%

Insider Ownership

0.00%

Institutional Own.

3.30%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

Setanaxib (NOX1/NOX4 inhibitor) Details
Primary biliary cholangitis, Liver disease

Phase 2/3

Data readout

Phase 2

Data readout

Setanaxib (NOX1/NOX4 inhibitor) Details
Idiopathic pulmonary fibrosis

Phase 2

Data readout

Setanaxib (NOX1/NOX4 inhibitor) Details
Cancer, Solid tumor/s, Head and neck squamous cell carcinoma

Phase 2

Update